

**MARYLAND PRESCRIPTION DRUG AFFORDABILITY STAKEHOLDER COUNCIL
VIRTUAL MEETING
December 16, 2024
Minutes**

Agenda Item 1

Call to Order:

Co-Chair Lorriane Diana called the meeting to order at 2:02 PM.

(Roll Call) Stakeholder Council Members Present:

Angela Bryant, Lorraine Diana, John Elliot, Sherita Golden, Jim Gutman, Deron Johnson, NaShona Kess, Barry Lipsy, Eric Morse, Marc Nicole, Shaun O'Brien, Mandi Poplawski, Glenn Schneider, Kelly Schulz, Sean Tunis, Joseph Winn

Agenda Item 2

November 4, 2024 Meeting Minutes

Co-Chair Diana asked for a motion to approve the November 4, 2024 meeting minutes as submitted. Shaun O'Brien made the motion, which Jim Gutman seconded. The PDASC approved the minutes unanimously.

Action: Minutes APPROVED

Agenda Item 3

Opportunity for Public Comment

The PDASC received no written comments and no requests for oral public comment.

Agenda Item 4

Upper Payment Limit Update- Presentation

Health Policy Analyst Christina Shaklee and Executive Director York gave an update on Upper Payment Limits. This presentation included previous actions taken to move the Upper Payment Limit process forward and the status of the draft regulations that were posted on October 28, 2024 to the PDAB website.

These regulations included: Amendments to COMAR 14.01.01.01 (Definitions), COMAR 14.01.01.06 (Hearing Procedures), and COMAR 14.01.05 (Policy Review, Final Action, Upper Payment Limits). Comments were due on the draft regulations on November 8, 2024.

Dr. York addressed specific comments received and PDASC feedback that was provided at the November 4, 2024 meeting in regards to these draft regulations. Dr. York presented updates to the regulations and the changes made to incorporate specific feedback and comments. This presentation is posted on the Stakeholder Council page of the PDAB website.

The PDASC provided feedback and asked specific questions regarding the regulations and the Upper Payment Limit process. There were multiple comments around unintended consequences on setting Upper Payment Limits. Delegate Bonnie Cullison provided feedback as well regarding this topic. PDAB staff will continue to work through comments and concerns.

Agenda Item 5

Cost Review Study Process- Presentation

Dr. York provided a verbal update on the Cost Review Study Process. Farxiga and Jardiance will be the first two drugs going through the Cost Review Study Process and then Ozempic and Trulicity. PDAB staff will post Cost Review Study information as it becomes available. There was a short discussion around SGLT-2 inhibitors and therapeutic alternatives.

Agenda Item 6

Administrative Update

Ms. Shaklee provided an administrative update on the following:

- The Board will meet virtually on January 27, 2025 at 2:00 PM.
- The PDASC meeting dates for 2025 are posted on the PDAB website.
- PDAB staff expressed appreciation to PDASC members for their hard work throughout the year.

Agenda Item 7

Co-Chair's Update

Co-Chair Diana stated that the next PDASC meeting will be held virtually on Monday, February 24, 2025 at 2:00 PM.

Agenda Item 8

Adjournment

Co-Chair Diana thanked everyone for attending the meeting and asked for a motion to adjourn the meeting. Shaun O'Brien made the motion which was seconded by Sherita Golden.

Adjourned at 2:51 PM.